Free Trial
NASDAQ:ADTX

Aditxt Earnings Date & Estimates

Aditxt logo
$0.0005 +0.00 (+66.67%)
As of 10:50 AM Eastern

Aditxt is estimated to report earnings on Wednesday, December 2, 2026.

What Analysts Expect from Aditxt

Aditxt is expected to post earnings of -$24,408,000,000.00 per share on revenue of $1 million.

Consensus Estimates

Consensus EPS
-$24,408,000,000.00
Expected Revenue
$1 million

Recent Track Record

Last Reported
Q4 2025
Last Quarter EPS
$315,563.31

Aditxt Earnings FAQ

Aditxt (NASDAQ:ADTX) is estimated to report earnings on Wednesday, December 2, 2026. This date is estimated from past reporting schedules and may change once the company confirms it.

Analysts expect Aditxt to post earnings of -$24,408,000,000.00 per share for the quarter.

The consensus revenue estimate for Aditxt is $1 million for the quarter.

Aditxt Earnings Headlines

Aditxt Faces Nasdaq Delisting, Moves Fully to OTC
Top Trader Reveals Stunning Black Friday Deal
Others paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Trading's Thomas Wood calls it one of the firm's most powerful proprietary trading indicators, and says the company has never run a deal like this before. There are no strings attached, just a steep Black Friday discount on a tool built for traders.tc pixel
Aditxt Stock Dividends | NASDAQ:ADTX | Benzinga
See More Aditxt Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Aditxt? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aditxt and other key companies, straight to your email.

About Aditxt

Aditxt (NASDAQ:ADTX) (NASDAQ: ADTX) is a biotechnology company focused on developing technologies designed to monitor and improve the human immune system. Its work centers on immune profiling, precision health and personalized medicine, with the goal of helping healthcare providers and researchers better understand individual immune responses.

The company’s primary technology platform, AditxtScore, is designed to analyze multiple immune system biomarkers simultaneously. The platform is intended for applications including disease detection, monitoring immune responses to infections and vaccines, and supporting the development of personalized treatment strategies. Aditxt has also pursued diagnostic and health-monitoring initiatives through related businesses and partnerships.

Aditxt was founded in 2017 and is headquartered in Mountain View, California. The company has identified Amro Albanna, its co-founder and chief executive officer, as part of its leadership. Its activities primarily serve the biotechnology, clinical research and healthcare markets, although the availability and development stage of specific products may vary by program and regulatory status.

View Aditxt Profile